Navigation Links
Accelrys Hosts Analyst Day, Updates Calendar Year 2013 Outlook
Date:9/12/2013

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL) today announced that its executive management team will host its 2013 analyst day today at its new corporate headquarters in San Diego.  In conjunction with the analyst day, Accelrys is providing an updated outlook for calendar year 2013 as a result of its acquisition of ChemSW, Inc. announced last week.

(Logo: http://photos.prnewswire.com/prnh/20120416/MM88629LOGO)

Updated Calendar Year 2013 Outlook:
Accelrys is updating its guidance for calendar year 2013.  For the year ending Dec. 31, 2013, the Company expects non-GAAP revenue to be between $177 million and $181 million, and non-GAAP earnings per share to be between $0.32 and $0.34 per diluted share on fully diluted weighted average shares outstanding of 57 million and using an effective tax rate of 40 percent.

Analyst Day Agenda:
Below is the analyst day agenda as well as a link to the prepared materials that will be used during the analyst day presentations. The materials will be made available on the morning of the meeting.  The analyst day will not be webcast. Accelrys welcomes Chris L. Waller, Ph. D., director of cheminformatics at Merck, as a special guest speaker.

  • Welcome and Introductions
  • Corporate Headquarters Tour – Jack Young, vice president of information technology
  • State of the Company – Max Carnecchia, CEO
  • Product Architecture & Strategy – Matt Hahn, chief technology officer
  • Product Marketing & Management – Leif Pedersen, senior vice president of marketing, product management and corporate development
  • Field Operations – Mollie Hunter, senior vice president, global sales and services
  • Lunch – Guest Speaker – Chris L. Waller, Ph.D., director, cheminformatics at Merck
  • Software Development – Scott Hiraoka, senior vice president, software development
  • Financial Update – Michael Piraino, chief financial officer
  • M&A –Sanjay Gupta, vice president, corporate and business development & Michael Piraino, CFO
  • Panel Q&A – Accelrys Management

Analyst Day Presentations:
The accompanying corporate presentations to the above-referenced analyst day sessions can be accessed at www.accelrys.com in the investor relations section of the site.

Attendance for this event requires an invitation and pre-registration, as space is limited. For more information on the process to attend the event in the future, please contact the MKR Group, Accelrys' investor relations firm.

About Accelrys:
Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit http://www.accelrys.com.

Forward-Looking Statements:
Statements contained in this press release relating to the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future, including, but not limited to, statements relating to the Company's expected non-GAAP revenue and diluted earnings per share for the year ending Dec. 31, 2013 and statements relating to the Company's long-term prospects and execution of its strategic growth initiatives, are forward-looking statements.  Such forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks that the Company will not achieve its expected non-GAAP revenue or diluted earnings per share for the year ending Dec. 31, 2013 and/or that the Company will not successfully execute its strategic growth initiatives, in each case due to, among other possibilities, an inability to withstand negative conditions in the global economy or a lack of demand for or market acceptance of the Company's products.  Additional risks and uncertainties faced by the Company are contained from time to time in the Company's filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended December 31, 2012, quarterly reports on Form 10-Q and current reports on Form 8-K. Collectively, these risks and uncertainties could cause the Company's actual results to differ materially from those projected in its forward-looking statements, and the Company disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Accelrys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Albert Einstein College of Medicine hosts conference on Jewish genetic research
2. BGI hosts its 2nd International Conference on Genomics in the Americas
3. Prehistoric ghosts revealing new details
4. New coronavirus has many potential hosts, could pass from animals to humans repeatedly
5. Einstein hosts its first stem cell institute symposium
6. Danforth Plant Science Center hosts 14th Annual Fall Symposium
7. FAPESP hosts meeting to discuss IPCC SREX report in São Paulo, Brazil
8. Urinary tract infections steal from hosts defense arsenals
9. Parasitic plants steal genes from their hosts
10. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
11. Ohio state hosts national energy conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology: